An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vyzulta

Chemical Namelatanoprostene bunod ophthalmic solution
Dosage FormSolution (topical ophthalmic; 0.24 mg/mL (0.024%))
Drug ClassOphthalmic agents
SystemOcular
CompanyBausch & Lomb
Approval Year2017

Indication

  • Vyzulta is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Last updated on 10/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyzulta (latanoprostene bunod ophthalmic solution) Prescribing Information2019Bausch & Lomb
Document TitleYearSource
Latanoprost Bunod (Vyzulta) - Clinical review report.2019CADTH
Latanoprost Bunod (Vyzulta) – Pharmacoeconomic review report.2019CADTH